New radioactive therapy shows promise for Hard-to-Treat cancers
NCT ID NCT05723640
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This early-stage study tested a new radioactive drug called 177Lu-LNC1004 in 11 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug is safe and to find the best dose for future studies. Participants received up to 4 doses over two cycles, with each dose given every 6 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, UNSPECIFIED, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Cancer Institute, Singapore National University Hospital, Singapore.
Singapore, 119077, Singapore
Conditions
Explore the condition pages connected to this study.